{"id":805681,"date":"2026-04-29T17:19:01","date_gmt":"2026-04-29T17:19:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=805681"},"modified":"2026-04-29T17:19:01","modified_gmt":"2026-04-29T17:19:01","slug":"atopic-dermatitis-clinical-trial-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-domain-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atopic-dermatitis-clinical-trial-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-domain-delveinsight_805681.html","title":{"rendered":"Atopic Dermatitis Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777477698.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Atopic Dermatitis Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777477698.jpg\" alt=\"Atopic Dermatitis Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Atopic Dermatitis Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Curious about the latest updates in the Atopic Dermatitis Pipeline? @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Atopic Dermatitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On April 27, 2026- Triveni Bio<\/em><\/strong> conducted a phase 2A study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.<\/li>\n<li><strong><em>On April 24, 2026- UCB Biopharma SRL<\/em><\/strong> announced a study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).<\/li>\n<li><strong><em>On April 23, 2026- Kymera Therapeutics Inc<\/em><\/strong>. initiated a phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.<\/li>\n<li><strong><em>On April 20, 2026- Apogee Therapeutics Inc<\/em><\/strong>. conducted a study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.<\/li>\n<li><strong><em>On April 17, 2026- Eli Lilly and Company <\/em><\/strong>announced a phase 4 study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.<\/li>\n<li>DelveInsight&rsquo;s Atopic Dermatitis Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Atopic Dermatitis treatment.<\/li>\n<li>The leading Atopic Dermatitis Companies such as <strong><em>Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics <\/em><\/strong>and others.<\/li>\n<li>Promising Atopic Dermatitis Therapies such as <strong><em>Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Want to know which companies are leading innovation in Atopic Dermatitis? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Atopic Dermatitis Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The Atopic Dermatitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Atopic Dermatitis Pipeline Report also highlights the unmet needs with respect to the Atopic Dermatitis.<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word &lsquo;dermatitis,&rsquo; &lsquo;derm&rsquo; means &lsquo;skin&rsquo; and &lsquo;itis&rsquo; means &lsquo;inflammation.&rsquo; Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ICP-332: Innocare Pharma<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>APG777: Apogee Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Barzolvolimab: Celldex Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ATI-2138: Aclaris Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK\/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK\/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>STAR-0310: Astria Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.<\/p>\n<p style=\"text-align: justify;\"><strong>If you&rsquo;re tracking ongoing Atopic Dermatitis Clinical trials, this press release is a must-read @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Atopic Dermatitis Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Atopic Dermatitis Pipeline report provides insights into:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.<\/li>\n<li>Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics <\/em><\/strong>and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Atopic Dermatitis Products have been categorized under various Molecule types such as,<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>From emerging drug candidates to competitive intelligence, the Atopic Dermatitis Pipeline Report covers it all &ndash; check it out now @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Atopic Dermatitis Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Atopic Dermatitis Companies- <strong><em>Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics <\/em><\/strong>and others.<\/li>\n<li>Atopic Dermatitis Therapies- <strong><em>Dupilumab, betamethasone valerate, GW842470X cream, LAS 41002, Hydrocortisone Ointment, Clobetasol Ointment, TAVO101, Apremilast, HY209GEL<\/em><\/strong>, and others.<\/li>\n<li>Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay ahead in Healthcare Research &ndash; discover what&rsquo;s next for the Atopic Dermatitis Treatment landscape in this detailed analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Atopic Dermatitis Emerging Drugs and Major Players<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Atopic Dermatitis: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Atopic Dermatitis&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>ICP-332: Innocare Pharma<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>APG777: Apogee Therapeutics<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>STAR-0310: Astria Therapeutics<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Inactive Products<\/li>\n<li>Atopic Dermatitis Key Companies<\/li>\n<li>Atopic Dermatitis Key Products<\/li>\n<li>Atopic Dermatitis- Unmet Needs<\/li>\n<li>Atopic Dermatitis- Market Drivers and Barriers<\/li>\n<li>Atopic Dermatitis- Future Perspectives and Conclusion<\/li>\n<li>Atopic Dermatitis Analyst Views<\/li>\n<li>Atopic Dermatitis Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=atopic-dermatitis-clinical-trial-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-domain-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-ad-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-ad-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=atopic-dermatitis-clinical-trial-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-domain-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s &ldquo;Atopic Dermatitis Pipeline Insight 2026&rdquo; report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/atopic-dermatitis-clinical-trial-pipeline-appears-robust-with-100-key-pharma-companies-actively-working-in-the-domain-delveinsight_805681.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,420],"tags":[],"class_list":["post-805681","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/805681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=805681"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/805681\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=805681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=805681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=805681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}